Skip to main content

Table 1 Clinical features of ENKTL-Breast cases

From: Extranodal natural killer/T-cell lymphoma of the breast: a retrospective clinicopathological analysis of a consecutive 11-year case series

Case P/S Age/sex Side Site Size (cm) Other sites involvement BM Stage B-symptoms LDH (IU/L) EBV –DNA (copies/ml) Concomitant diseases Treatment Follow-Up*
1 P 31/F R areola 5.7 × 3.5 An isolated right axillary node involvement at the diagnosis of primary ENKTL-Breast Normal I Yes 311 1.81 × 104 IgA nephropathy GemxoD + Pe Died (9 mo)
2 P 26/F R UOQ 4.0 × 3.0 Both side of the lungs and the liver were involved one and a half months after the diagnosis of primary ENKTL-Breast Normal I Yes 787 1.40 × 103 Chronic active hepatitis B GDP Died (3 mo)
3 P 54/F L UOQ 2.0 × 2.0 None Normal I No NA NA NA NA LTF
4 S 30/F L UOQ 2.5 × 2.0 Breast involvement appeared 20 months after the diagnosis of primary vagina ENKTL Normal IV Yes 449 1.30 × 104 None GLIDE + RT, followed by GMOX + Ca Died (6 mo)
5 S 57/F R UOQ 1.0 × 1.0 Breast involvement appeared 8 months after the diagnosis of primary nasal ENKTL Normal IV Yes 160 Negative None VDLP, followed by SMILE + RT Died (5 mo)
6 S 46/F R UOQ 2.8 × 2.0 Breast involvement appeared 12 months after the diagnosis of primary nasal ENKTL NA IV Yes NA NA None NA LTF
7 S 63/F B UOQ R,2.0 × 2.0
L,5.0 × 3.0
NA NA ND Yes NA NA None NA Died (11 mo)
8 S 39/F R UOQ 2.0 × 1.0 Simultaneous involvement of GI tract and the breast NA IV Yes 982 NA Graves’ disease NA Died (2 mo)
  1. *The Follow-Up time was calculated from the time of diagnosing ENKTL-Breast. The stage was measured at the time of diagnosing ENKTL-breast
  2. Patients with a history of ENKTL had just an isolated lesion (stage I) at the time of diagnosis from the primary site
  3. B, bilateral; BM, bone marrow; Ca, Camrelizumab; F, female; GDP, gemcitabine + cisplatin + dexamethasone; GemxoD, gemcitabine + oxaliplatin + dexamethasone; GLIDE, gemcitabine + L-asparaginase + ifosfamide + dexamethasone; GMOX, gemcitabine + oxaliplatin; GI, gastrointestinal; L, left; LTF, lost to follow-up; mo, month; NA, not available; ND, not done; Pe, pegaspargase; P, Primary; R,right; RT, radiotherapy; S, Secondary; SMILE, methotrexate + dexamethasone + fosfamide + pegaspargase + etoposide + mesna; UOQ, upper outer quadran; VDLP, etoposide + cisplatin + dexamethasone + pegaspargase